Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
221 hedge funds and large institutions have $176M invested in Sorrento Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 41 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
48% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $2.42M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 233 → 221 (-12)
20% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 41
32% less capital invested
Capital invested by funds: $260M → $176M (-$84.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.31M |
| 3 |
BlackRock
New York
|
+$6.96M |
| 4 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$6.92M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.79M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.66M |
| 3 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$1.24M |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.1M |
| 5 |
Citigroup
New York
|
-$1.03M |
SRNE Hedge Fund Activity: Q4 2022 in Review
221 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2022, worth a combined $176M — down 32% from $260M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of SRNE and 33 opened new positions — a net loss of 8 holders — while 48 trimmed existing stakes and 75 added.
The largest buyer was State Street, adding an estimated $13.2M. The largest seller was Citadel Advisors, cutting an estimated $1.79M.
- 221 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2022, down from 233 in Q3 2022.
- Funds reported $176M of Sorrento Therapeutics, Inc. stock for Q4 2022, down 32% quarter-over-quarter.
- 33 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2022 and 41 closed out, a net change of -8 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2022 was State Street, an estimated $13.2M added.
- The largest Sorrento Therapeutics, Inc. seller in Q4 2022 was Citadel Advisors, an estimated $1.79M sold.
Based on aggregated 13F filings for Q4 2022.